Rasopathies: Developmental disorders that predispose to cancer and skin manifestations;Rasopatías: Trastornos del desarrollo con predisposición al cáncer y manifestaciones cutáneas

Actas Dermo-Sifiliograficas

Volumn 102, Issue 6, 2011, Pages 402-416

  Hernandez Martin A ^a   Torrelo, A ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

RAS Mitogen activated protein kinase pathway; Rasopathies

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

CANCER SUSCEPTIBILITY; CARDIOFACIOCUTANEOUS SYNDROME; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COSTELLO SYNDROME; DEVELOPMENTAL DISORDER; FACE DYSMORPHIA; GENE MUTATION; HEART DISEASE; HUMAN; LEARNING DISORDER; LEGIUS SYNDROME; LEOPARD SYNDROME; MENTAL DEFICIENCY; NEUROFIBROMATOSIS; NOONAN SYNDROME; RASOPATHY; REVIEW; SKIN MALFORMATION; SKIN MANIFESTATION; SOMATIC MUTATION; SYNDROME; GENETIC PREDISPOSITION; GENETICS; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION; SKIN DISEASE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; NEOPLASMS; RAS PROTEINS; SKIN DISEASES; SYNDROME;

EID: 79958716830     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2011.02.010     Document Type: Short Survey

References (111)

1. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA. 1982;79:3637-40. (Pubitemid 12014525)
2. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19:230-326.
3. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153-208. (Pubitemid 32098004)
4. Barbacid M. Ras Genes. Annu Rev Biochem. 1987;56:779-827.
5. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta. 2002;1602:23-45. (Pubitemid 34311898)
6. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-65. (Pubitemid 37328850)
7. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem. 2005;386:193-205. (Pubitemid 40485425)
8. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21-44. (Pubitemid 43108774)
9. Bos JL. Ras Oncogenes in Human Cancer: a Review. Cancer Res. 1989;49:4682-9. (Pubitemid 19213607)
10. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
11. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007;44:763-71. (Pubitemid 350275049)
12. Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA. 2007;104:8953-8. (Pubitemid 47175418)
13. Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev. 2005;15:265-9. (Pubitemid 40726049)
14. Hart TC, Zhang Y, Gorry MC, Hart PS, Cooper M, Marazita ML, et al. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am J Hum Genet. 2002;70:943-54. (Pubitemid 34259310)
15. Mukhopadhyay A, Krishnaswami SR, Yu BD. Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol. 2010;131:311-9.
16. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2-26.
17. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009;30:695-702.
18. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-8. (Pubitemid 34326699)
19. Tidyman WE, Rauen KA. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes. Methods Mol Biol. 2010;661:433-47.
20. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29:992-1006.
21. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39:70-4. (Pubitemid 46026503)
22. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39: 75-9. (Pubitemid 46026504)
23. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007-12. (Pubitemid 47185177)
24. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010;42:27-9.
25. Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009;41:1022-6.
26. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. 2010;87:250-7.
27. Allanson JE. Noonan syndrome. Am J Med Genet C Semin Med Genet. 2007;145C:274-9. (Pubitemid 47291936)
28. Allanson JE, Bohring A, Dorr HG, Dufke A, Gillessen-Kaesbach G, Horn D, et al. The face of Noonan syndrome: Does phenotype predict genotype. Am J Med Genet A. 2010;152A:1960-6.
29. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr. 2004;144:368-74. (Pubitemid 38333896)
30. Witt DR, Hoyme HE, Zonana J, Manchester DK, Fryns JP, Stevenson JG, et al. Lymphedema in Noonan syndrome: clues to pathogenesis and prenatal diagnosis and review of the literature. Am J Med Genet. 1987;27:841-56. (Pubitemid 17151149)
31. Ramaswamy PV, Storm CA, Filiano JJ, Dinulos JG. Multiple granular cell tumors in a child with Noonan syndrome. Pediatr Dermatol. 2010;27:209-11.
32. Lee WJ, Lee DW, Yang JH, Chang SE, Lee MW, Choi JH, et al. Novel occurrence of microcystic lymphatic malformation and linear port-wine stain in patients with Noonan syndrome. Int J Dermatol. 2010;49:232-3.
33. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm Res. 2009;72 Suppl2:8-14.
34. Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, et al. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer. 2008;47:253-9. (Pubitemid 351162856)
35. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol. 2007;100:736-41. (Pubitemid 47223154)
36. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.
37. Sarkozy A, Conti E, Digilio MC, Marino B, Morini E, Pacileo G, et al. Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet. 2004;41:e68.
38. Digilio MC, Sarkozy A, de Zorzi A, Pacileo G, Limongelli G, Mingarelli R, et al. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A. 2006;140:740-6.
39. Rodríguez-Bujaldón A, Vázquez-Bayo C, Jiménez-Puya R, Galán-Gutiérrez M, Moreno-Giménez J, Rodríguez-García A, et al. LEOPARD syndrome: what are café noir spots? Pediatr Dermatol. 2008;25:444-8.
40. Seishima M, Mizutani Y, Shibuya Y, Arakawa C, Yoshida R, Ogata T. Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation. Br J Dermatol. 2007;157:1297-9. (Pubitemid 350115702)
41. Theos A, Korf BR. American College of Physicians, American Physiological Society. Pathophysiology of neurofibromatosis type 1. Ann Intern Med. 2006;144:842-9.
42. Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, et al. Screening 500 unselected neuro-fibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat. 2004;23:111-6. (Pubitemid 38200601)
43. Descheemaeker MJ, Roelandts K, De Raedt T, Brems H, Fryns JP, Legius E. Intelligence in individuals with a neurofibromatosis type 1 microdeletion. Am J Med Genet A. 2004;131: 325-6.
44. Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Hogel J, et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010;47:623-30.
45. De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288-92. (Pubitemid 36530016)
46. Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007;80:140-51. (Pubitemid 46047657)
47. Riccardi VM. Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1). Am J Hum Genet. 1993;53:301-4. (Pubitemid 23308923)
48. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61:1-14, quiz 15-6.
49. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105(3 Pt 1):608-14. (Pubitemid 30129679)
50. Whitehouse D. Diagnostic value of the cafe-au-lait spot in children. Arch Dis Child. 1966;41:316-9.
51. Boyd KP, Gao L, Feng R, Beasley M, Messiaen L, Korf BR, et al. Phenotypic variability among cafe-au-lait macules in neurofibromatosis type 1. J Am Acad Dermatol. 2010;63:440-7.
52. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355-81.
53. Zeller J, Wechsler J, Revuz J, Wolkenstein P. Blue-red macules and pseudoatrophic macules in neurofibromatosis 1. Ann Dermatol Venereol. 2002;129:180-1.
54. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology. 2001;56:1433-43. (Pubitemid 32532254)
55. Consoli C, Moss C, Green S, Balderson D, Cooper DN, Upadhyaya M. Gonosomal mosaicism for a nonsense mutation (R1947X) in the NF1 gene in segmental neurofibromatosis type 1. J Invest Dermatol. 2005;125:463-6.
56. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-4. (Pubitemid 34526349)
57. Johnson RE, Kanigsberg ND, Jiménez CL. Localized pruritus: a presenting symptom of a spinal cord tumor in a child with features of neurofibromatosis. J Am Acad Dermatol. 2000;43(5 Pt 2):958-61.
58. Coffin CM, Cassity J, Viskochil D, Randall RL, Albritton K. Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A. 2004;127A:40-3. (Pubitemid 38937204)
59. Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10:508-15.
60. Burgdorf WH, Zelger B. JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr Dermatol. 2004;21:174-6.
61. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39:1120-6. (Pubitemid 47340658)
62. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature. 2001;412:647-51. (Pubitemid 32772277)
63. Denayer E, Chmara M, Brems H, Kievit AM, van Bever Y, Van den Ouweland AM, et al. Legius syndrome in fourteen families. Hum Mutat. 2011;32:E1985-1998.
64. Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet. 2009;46:425-30.
65. Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009;302: 2111-8.
66. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37:1038-40. (Pubitemid 41486653)
67. Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott Jr CI, Doyle D, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A. 2006;140:1-7. (Pubitemid 43054028)
68. Huang MY, Cohen JB. The alternative H-ras protein p19 displays properties of a negative regulator of p21Ras. Oncol Res. 1997;9:611-21. (Pubitemid 127787912)
69. Guil S, Gattoni R, Carrascal M, Abian J, Stevenin J, Bach-Elias M. Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol. 2003;23:2927-41.
70. Sol-Church K, Stabley DL, Nicholson L, González IL, Gripp KW. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat. 2006;27:736-41. (Pubitemid 44205066)
71. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, et al. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat. 2007;28:265-72.
72. Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A. 2006;140:2163-9. (Pubitemid 44522430)
73. Girisha KM, Lewis LE, Phadke SR, Kutsche K. Costello syndrome with severe cutis laxa and mosaic HRAS G12S mutation. Am J Med Genet A. 2010;152A:2861-4.
74. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010;152A:4-24.
75. Gripp KW, Innes AM, Axelrad ME, Gillan TL, Parboosingh JS, Davies C, et al. Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A. 2008;146A:683-90. (Pubitemid 351354143)
76. Viosca J, Schuhmacher AJ, Guerra C, Barco A. Germline expression of H-Ras(G12 V) causes neurological deficits associated to Costello syndrome. Genes Brain Behav. 2009;8:60-71.
77. Lurie IW. Genetics of the Costello syndrome. Am J Med Genet A. 1994;52:358-9. (Pubitemid 24280022)
78. Johnson JP, Golabi M, Norton ME, Rosenblatt RM, Feldman GM, Yang SP, et al. Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr. 1998;133:441-8. (Pubitemid 28413632)
79. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44:131-5.
80. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat. 2011;32:33-43.
81. Rauen KA. Distinguishing Costello versus cardio-faciocutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet A. 2006;140:1681-3. (Pubitemid 44148257)
82. Rauen KA. HRAS and the Costello syndrome. Clin Genet. 2007;71:101-8. (Pubitemid 46189213)
83. Lin AE, Grossfeld PD, Hamilton RM, Smoot L, Gripp KW, Proud V, et al. Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet A. 2002;111:115-29. (Pubitemid 34809491)
84. Vila Torres J, Pineda Marfa M, González Ensenat MA, Lloreta Trull J. Pathology of the elastic tissue of the skin in Costello syndrome. An image analysis study using mathematical morphology. Anal Quant Cytol Histol. 1994;16:421-9.
85. Hinek A, Smith AC, Cutiongco EM, Callahan JW, Gripp KW, Weksberg R. Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67-kD elastin-binding protein. Am J Med Genet A. 2000;66:859-72. (Pubitemid 30470489)
86. Mori M, Yamagata T, Mori Y, Nokubi M, Saito K, Fukushima Y, et al. Elastic fiber degeneration in Costello syndrome. Am J Med Genet A. 1996;61:304-9.
87. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005;137C:72-7. (Pubitemid 41113664)
88. Gripp KW, Scott Jr CI, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet A. 2002;108:80-7.
89. Rodríguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311:1287-90. (Pubitemid 43334718)
90. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006;38:294-6.
91. Plowman SJ, Hancock JF. Ras signaling from plasma membrane and endomembrane microdomains. Biochim Biophys Acta. 2005;1746:274-83. (Pubitemid 41815021)
92. Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A. 2007;143A:799-807. (Pubitemid 46556165)
93. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, et al. The cardiofaciocutaneous syndrome. J Med Genet. 2006;43:833-42. (Pubitemid 44787108)
94. Siegel DH, McKenzie J, Frieden IJ, Rauen KA. Dermatologic Findings in 61 Mutation-Positive Individuals with Cardio-faciocutaneous Syndrome. Br J Dermatol. 2011;164:521-9.
95. Terao M, Sakai N, Higashiyama S, Kotobuki Y, Tanemura A, Wataya-Kaneda M, et al. Cutaneous symptoms in a patient with cardiofaciocutaneous syndrome and increased ERK phosphorylation in skin fibroblasts. Br J Dermatol. 2010;163:881-4.
96. Jeffries ML, Aleck KA, Bernert RA, Hansen RC. Eccrine squamous metaplasia and periadnexal granulomas: new cutaneous histopathologic findings in cardiofaciocutaneous syndrome. Pediatr Dermatol. 2010;27:274-8.
97. Van Den Berg H, Hennekam RC. Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. J Med Genet. 1999;36:799-800.
98. Makita Y, Narumi Y, Yoshida M, Niihori T, Kure S, Fujieda K, et al. Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. J Pediatr Hematol Oncol. 2007;29:287-90. (Pubitemid 46707505)
99. Al-Rahawan MM, Chute DJ, Sol-Church K, Gripp KW, Stabley DL, McDaniel NL, et al. Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. Am J Med Genet A. 2007;143A:1481-8. (Pubitemid 47051027)
100. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98:194-200.
101. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89: 1341-8. (Pubitemid 27079998)
102. Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Med Genet A. 2003;73:1240-9. (Pubitemid 38037418)
103. Denayer E, de Ravel T, Legius E. Clinical and molecular aspects of RAS related disorders. J Med Genet. 2008;45:695-703.
104. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6:313-9. (Pubitemid 39361432)
105. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54. (Pubitemid 34716871)
106. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev. 2007;17:23-30. (Pubitemid 46131442)
107. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529-45.
108. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-90.
109. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80:624-37.
110. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95: 581-6. (Pubitemid 44325897)
111. Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, et al. Back to the future: Proceedings from the 2010 NF Conference. Am J Med Genet A. 2010;155: 307-21.